利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.03 秒)

    NOISE CANCELLATION SYSTEM
    1.
    发明申请
    NOISE CANCELLATION SYSTEM 有权
    噪声消除系统

    公开(公告)号：US20160027428A1

    公开(公告)日：2016-01-28

    申请号：US14800308

    申请日：2015-07-15

    申请人： Hassan Faqir Gul ,  Nigel Greig ,  Thomas Allen Darbonne ,  Mark Poletti ,  Johann Frederic de Guigne

    发明人： Hassan Faqir Gul ,  Nigel Greig ,  Thomas Allen Darbonne ,  Mark Poletti ,  Johann Frederic de Guigne

    IPC分类号： G10K11/178

    CPC分类号： G10K11/1788 ,  G10K11/178 ,  G10K2210/108 ,  G10K2210/1281 ,  G10K2210/3221 ,  H04R1/1083 ,  H04R5/023 ,  H04R5/027 ,  H04R27/00 ,  H04R2227/001 ,  H04R2410/05 ,  H04R2499/13

    摘要： Active noise cancellation may be provided by a variety of systems, methods and techniques. General aspects, for example, include an active noise cancellation system, a controller for an active noise cancellation system, and/or a method of generating an anti-noise signal. In one example aspect, an active noise cancellation system for an aircraft In-flight entertainment system may include at least one input device, a processing means, and an output. The input device may be associated with a seat on the aircraft and adapted to receive an input representative of an ambient noise in the vicinity of the seat. The processing means may be adapted to process the input to produce an output signal adapted to reduce the ambient noise in volume associated with the seat. The output may be adapted to transmit an output signal to at least one driver, which is adapted to transmit the output signal to a user.

    摘要翻译： 主动噪声消除可以通过各种系统，方法和技术来提供。 一般方面，例如包括有源噪声消除系统，用于主动噪声消除系统的控制器和/或产生抗噪声信号的方法。 在一个示例方面，用于飞行器飞行娱乐系统的主动噪声消除系统可以包括至少一个输入设备，处理装置和输出。 输入设备可以与飞机上的座椅相关联并且适于接收代表座椅附近的环境噪声的输入。 处理装置可以适于处理输入以产生适于减少与座椅相关的体积的环境噪声的输出信号。 输出可以适于将输出信号发送到至少一个驱动器，其适于将输出信号发送给用户。

    AIRLINE PASSENGER SEAT MODULAR USER INTERFACE DEVICE
    4.
    发明申请
    AIRLINE PASSENGER SEAT MODULAR USER INTERFACE DEVICE 有权
    航空乘客座椅模块化用户界面设备

    公开(公告)号：US20120039048A1

    公开(公告)日：2012-02-16

    申请号：US13109143

    申请日：2011-05-17

    申请人： Christopher K. Mondragon ,  Nigel Greig ,  Edward Scholten ,  Roy Moody ,  Paul Simmonds ,  Elaine Clarke ,  Thomas Allen Darbonne

    发明人： Christopher K. Mondragon ,  Nigel Greig ,  Edward Scholten ,  Roy Moody ,  Paul Simmonds ,  Elaine Clarke ,  Thomas Allen Darbonne

    IPC分类号： H05K5/00 ,  H01R13/02

    CPC分类号： B64D11/0602 ,  B60N2/879 ,  B60N2002/0264 ,  B60R11/0235 ,  B60R2011/0012 ,  B64D11/0015 ,  B64D11/00153 ,  B64D11/0624

    摘要： A module carrier unit comprises a plurality of passenger interface modules that perform different functions, the functions including at least one of inputting and outputting information, the modules having a common size, shape, and interface; an outer case portion comprising a plurality of receptacles, each having a common size, shape, and interface designed to receive one of the modules, the plurality of receptacles being such that a first module having a first function is operable in a first receptacle, and a second module having a second function is operable in the first receptacle, the modules being removably connected to the receptacles; and a communications interface that performs at least one of transmitting and receiving data to and from a processor located near a seat of a passenger in the vehicle.

    摘要翻译： 模块承载单元包括执行不同功能的多个乘客接口模块，所述功能包括输入和输出信息中的至少一个，所述模块具有共同的大小，形状和接口; 外壳部分包括多个插座，每个插座具有设计成容纳模块之一的共同尺寸，形状和接口，所述多个插座使得具有第一功能的第一模块可在第一插座中操作，以及 具有第二功能的第二模块可在第一插座中操作，模块可拆卸地连接到插座; 以及通信接口，其执行向位于车辆中的乘客的座位附近的处理器发送和接收数据中的至少一个。

    Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods
    6.
    发明申请
    Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods 审中-公开
    可用于治疗或预防与糖尿病相关的认知障碍和相关方法的化合物

    公开(公告)号：US20060105940A1

    公开(公告)日：2006-05-18

    申请号：US11261121

    申请日：2005-10-28

    申请人： Nigel Greig ,  Gosse Bruinsma ,  Qian-Sheng Yu

    发明人： Nigel Greig ,  Gosse Bruinsma ,  Qian-Sheng Yu

    IPC分类号： A61K31/4439 ,  A61K31/426 ,  A61K31/407 ,  A61K38/28 ,  A61K31/155 ,  A61K31/175

    CPC分类号： C07D487/04 ,  A61K31/155 ,  A61K31/175 ,  A61K31/407 ,  A61K31/426 ,  A61K31/4439 ,  A61K38/28 ,  A61K2300/00

    摘要： Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (−)-(3aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N—4′-isopropylphenylcarbamate (“MHI tartrate”), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects may be suffering from or predicted to suffer from abnormal acetylcholinesterase and/or butyrylcholinesterase activity levels or from an inability to metabolize or catabolize blood sugar normally. The method comprises administering to the subject an effective amount of MHI tartrate dispensable in discrete pharmaceutically useful dosages. MHI tartrate effectively inhibits both acetylcholinesterase and butyrylcholinesterases and additionally is highly selective for butyrylcholinesterase over acetylcholinesterase.

    摘要翻译： 描述了一种易于操作和利用有效的可逆丁酰胆碱酯酶抑制剂（ - ） - （3aS）-3a-甲基-1,2,3,3a，8,8a-六氢吡咯并 - [2,3-b]吲哚-5-基N-4'-异丙基苯基氨基甲酸酯（“MHI酒石酸盐”），用于改变显示或预测显示与...相关的认知障碍的受试者中丁酰胆碱酯酶和/或乙酰胆碱酯酶的酶活性 糖尿病。 受试者可能患有或预测患有乙酰胆碱酯酶异常和/或丁酰胆碱酯酶活性水平或不能正常代谢或分解代谢血糖。 该方法包括向受试者施用有效量的以分散的药学上有用的剂量分配的有效量的酒石酸氢盐。 MHI酒石酸盐有效抑制乙酰胆碱酯酶和丁酰胆碱酯酶，另外对丁酰胆碱酯酶对乙酰胆碱酯酶的选择性高。

    Substituted phenserines as specific inhibitors of acetylcholinesterase
    9.
    发明授权
    Substituted phenserines as specific inhibitors of acetylcholinesterase 失效
    取代的苯西林作为乙酰胆碱酯酶的特异性抑制剂

    公开(公告)号：US5171750A

    公开(公告)日：1992-12-15

    申请号：US765746

    申请日：1991-09-26

    申请人： Arnold Brossi ,  Malgarzota Brzostowska ,  Stanley I. Rapoport ,  Nigel Greig ,  Xiao-shu He

    发明人： Arnold Brossi ,  Malgarzota Brzostowska ,  Stanley I. Rapoport ,  Nigel Greig ,  Xiao-shu He

    IPC分类号： C07D487/04 ,  C07D491/04 ,  C07D491/048

    CPC分类号： C07D487/04 ,  C07D491/04

    摘要： The present invention relates to substituted phenylcarbamate or naphthylcarbamate tricyclic compounds which provide highly potent and selective cholinergic agonist and blocking activity and their use as pharmaceutical agents. The invention further relates to improvements in therapy relative to cholinergic diseases such as glacuoma, Myasthenia Gravis, Alzheimer's disease and to improvements in therapy and organophosphate poisoning. The invention further provides for a selective acetylcholinesterase and butyrylcholinesterase agents and a method for inhibiting these esterases.

    摘要翻译： 本发明涉及提供高效和选择性胆碱能激动剂和阻断活性的取代的苯基氨基甲酸酯或萘基氨基甲酸三环化合物及其作为药剂的用途。 本发明还涉及治疗相对于胆碱能疾病如冰川，重症肌无力，阿尔茨海默病以及治疗和有机磷酸盐中毒方面的改进。 本发明进一步提供选择性乙酰胆碱酯酶和丁酰胆碱酯酶及其抑制这些酯酶的方法。

    GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF
    10.
    发明申请
    GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF 有权
    GLP-1，EXENDIN-4，肽类似物及其用途

    公开(公告)号：US20120329715A1

    公开(公告)日：2012-12-27

    申请号：US13594313

    申请日：2012-08-24

    申请人： Nigel Greig ,  Josephine Egan ,  Maire Doyle ,  Harold Holloway ,  Tracy Ann Perry

    发明人： Nigel Greig ,  Josephine Egan ,  Maire Doyle ,  Harold Holloway ,  Tracy Ann Perry

    IPC分类号： A61K38/26 ,  A61P25/00 ,  A61P25/28

    CPC分类号： C07K14/575 ,  A61K38/00 ,  A61K38/2278 ,  A61K38/26 ,  C07K14/57563

    摘要： The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

    摘要翻译： 本发明涉及GLP-1和毒蜥外泌肽-4的新型多肽类似物。 在优选的实施方案中，多肽是促胰岛素和长效的。 优选地，多肽的促胰岛素效应与等摩尔量的GLP-1或毒蜥外泌肽-4的作用相当或超过其作用。 本发明还涉及治疗患有糖尿病的受试者的方法，其包括向所述受试者施用具有促胰岛素作用的量的本发明的多肽。 本发明还涉及使用GLP-1，毒蜥外泌肽素-4及其多肽类似物用于神经保护和神经营养作用的方法。